Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis

This publication has 34 references indexed in Scilit:

• Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer
  Clinical Lung Cancer, 2012
• Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer
  Clinical Lung Cancer, 2012
• Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients
  Lung Cancer, 2012
• Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer
  Journal of Thoracic Oncology, 2012
• A basic introduction to fixed-effect and random-effects models for meta-analysis
  Research Synthesis Methods, 2010
• Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancer
  Cancer Science, 2008
• Expression and mutational analysis of MET in human solid cancers
  Genes, Chromosomes and Cancer, 2008
• Practical methods for incorporating summary time-to-event data into meta-analysis
  Trials, 2007
• Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer
  Cancer Research, 2006
• Quantifying heterogeneity in a meta‐analysis
  Statistics in Medicine, 2002